CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
NORTH CHICAGO, Ill., July 25, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has... Biopharmaceuticals, RegulatoryAbbVie, hepatitis C, VIEKIRAX
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Children | Cirrhosis | European Medicines Agency (EMA) | Grants | Hepatitis | Hepatitis C | Marketing | Norvir | Pharmaceuticals